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Abstract
Background: Diabetes is a disease of increasing worldwide prevalence and is the main cause of
chronic renal failure. Type 1 diabetic patients with chronic renal failure have the following therapy
options: kidney transplant from a living donor, pancreas after kidney transplant, simultaneous
pancreas-kidney transplant, or awaiting a deceased donor kidney transplant. For type 2 diabetic
patients, only kidney transplant from deceased or living donors are recommended. Patient survival
after kidney transplant has been improving for all age ranges in comparison to the dialysis therapy.
The main causes of mortality after transplant are cardiovascular and cerebrovascular events,
infections and neoplasias. Five-year patient survival for type 2 diabetic patients is lower than the
non-diabetics' because they are older and have higher body mass index on the occasion of the
transplant and both pre- and posttransplant cardiovascular diseases prevalences. The increased
postransplant cardiovascular mortality in these patients is attributed to the presence of well-known
risk factors, such as insulin resistance, higher triglycerides values, lower HDL-cholesterol values,
abnormalities in fibrinolysis and coagulation and endothelial dysfunction. In type 1 diabetic patients,
simultaneous pancreas-kidney transplant is associated with lower prevalence of vascular diseases,
including acute myocardial infarction, stroke and amputation in comparison to isolated kidney
transplant and dialysis therapy.
Conclusion: Type 1 and 2 diabetic patients present higher survival rates after transplant in
comparison to the dialysis therapy, although the prevalence of cardiovascular events and infectious
complications remain higher than in the general population.
Introduction
Diabetes is a disease of increasing worldwide prevalence,
with a perspective of 330 million people affected by 2030.
In the United States of America, diabetes is the main cause
of chronic kidney failure, corresponding to approximately
40% of the patients undergoing renal replacement ther-
apy and outgrowing the number of cases of nephritis and
systemic arterial hypertension (United States Renal Data
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been observed a change in the time interval from the dia-
betes diagnosis to the development of chronic kidney fail-
ure, which was shown to increase from 20 to 30 years [1].
In Brazil, it is estimated that there are 6 million diabetics
being 510% of these type 1 diabetic patients and the oth-
ers have type 2 diabetes. The worldwide incidence of type
1 diabetes is quite variable, but it is reported to be around
510% among those who are under 15 years old, and
nearly 10% in Brazil [2]. The inicidence of type 2 diabetes
has increased approximately by 52% from 1997 to 2003
in the United States of America [3].
Patients with type 1 diabetes and chronic kidney failure
have the following therapy options, besides the dialysis
treatment: kidney transplant from a living donor, pan-
creas transplant after kidney transplant, simultaneous
pancreas-kidney transplant, or awaiting a deceased donor
kidney transplant [4]. On the other hand, for type 2 dia-
betic patients is recommended kidney transplant from a
deceased or a living donor.
Isolated Kidney Transplant from a Living Donor for Type 1 
Diabetic Patients
The awaiting time is shorter in this transplant modiality
than in other ones because it takes just the time to prepare
the living donor. Imunossuppressive regimen may be tai-
lored according to the Human Leucocytes Antigens (HLA)
compatibility. If there is is an identical donor, the dose of
the immunosuppressors will be lower, which minimizes
their side effects. This is the transplant modality that has
the greatest life expectancy rate, around 18.3 years [4].
Isolated Kidney Transplant from a Deceased Donor for 
type 1 Diabetic Patients
In Brazil, the organ allocation for kidney transplant from
a deceased donor is determined by the HLA compatibility,
resulting in a waiting time that may be over five or six
years, which increases the secondary clinical complication
events, either related to the diabetes or to the chronic kid-
ney failure. The patient survival rate, although longer than
in dialysis, is around 11.4 years [4].
On the other hand, it has recently been discussed if the
comparison of the kidney survival can be done without a
bias between simultaneous pancreas-kidney transplant
and deceased donor kidney alone, inasmuch as there are
donor, recipient and transplant differences that may inter-
fere with the outcomes [5]. In this way, 5-year kidney graft
survival was demonstrated to be similar between recipi-
ents of simultaneous pancreas-kidney transplant and kid-
ney alone from pancreas donors (76.2% vs 81.9%,
respectively), whereas the kidney graft survival of the kid-
ney alone from non-pancreas donors was significantly
lower than the other two groups (64.3%). When control-
ling for recipient and transplant differences, it was
observed a reduction of 50% in the risk of kidney graft
loss in the group of kidney alone from pancreas donors in
comparison to simultaneous pancreas-kidney transplant
[5].
Pancreas after Kidney Transplant (PAKT) for type 1 
Diabetic Patients
Pancreas after kidney transplant (PAKT) modality has the
shortest waiting time for pancreas transplant in Brazil,
since many teams capture the pancreas, but do not per-
form the pancreas transplant surgical procedure, which
results in a shorter waiting time in comparison to simul-
taneous pancreas-kidney transplant. The life expectancy
rate is reported to be 17.2 years [4]. However, the greatest
challenge is to monitor the pancreatic rejection, inasmuch
as asynchronous pancreas rejection may occur.
Furthermore, PAKT indications are still controversial in
the literature, but they may be certainly indicated for cases
of severe asymptomatic hypoglycemia and ketoacidosis of
difficult control [4]. Therefore, the probability of hypogly-
cemia greater than 5% and the probability of death from
hypoglycemia greater than 9% justify the PAKT perform-
ance [4]. The PAKT is also indicated in cases when ketoac-
idosis becomes a frequent event (100.4 events for every
100 patients a year) [4].
In addition, it was recently demonstrated that the 1-year
patient survival after PAKT was similar to the simultane-
ous pancreas-kidney transplant (98% vs 95%, respec-
tively), as well as the 1-year pancreas graft survival (95%
vs 90%, respectively) [6]. The immunosuppressive regi-
men included rabbit anti-thymocyte globulin (thymo-
globulin), early steroid withdrawal and maintenance with
tacrolimus and sirolimus or mycophenolate mofetil.
Interestingly, the acute cellular rejection was present in
only 2% of the groups described. However, further studies
are necessary to evaluate the long-term pancreas graft sur-
vival rates after the PAKT.
Simultaneous Pancreas-Kidney Transplant (SPKT) for type 
1 Diabetic Patients
In type 1 diabetic patients under dialysis, the 5-year
patient survival, even for young patients, ranges from 25
to 35%, increasing to 80% after the transplant [7]. In this
way, the simultaneous pancreas-kidney transplant (SPKT)
for type 1 diabetic patients is a therapy that increases
patient survival. However, the type 1 diabetic patients
who received a kidney transplant have a death risk of 4.3
and a higher cardiovascular morbidity rate, which is
around 4.5, in comparison to the non-diabetic patients
[8].
Confirming the transplant benefits with regards to the life
expectancy of type 1 diabetic patients in comparison to
the dialysis therapy, it was demonstrated that patients thatPage 2 of 7
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8-year life expectancy as opposed to the patients that have
12.9-year, 21-year and 23-year life expectancies after the
kidney transplant from deceased donors, the kidney trans-
plant from living donors and the SPKT, respectively [9].
However, other authors reported a shorter life expectancy
after the SPKT in comparison to the kidney transplant
from living donors in type 1 diabetic patients [4]. It could
be in part explained by the higher mortality rate in the first
90 days after the SPKT, once the surgical and infectious
complications are more frequent [10,11].
Nowadays, the pancreas graft survival tends to be longer
after the SPKT. There was shown an increase from 75% to
85% in the pancreas graft survival rates in the first year as
compared to the other modalities of pancreas transplants,
such as pancreas transplant alone and PAKT, which
showed pancreas graft survival rates around 75% at 1-year
[12]. After the SPKT, the secondary complications in type
1 diabetic patients are reduced and it is reported to occur
clinical improvement in the carotid intima-media thick-
ness [13], coronary atherosclerosis [14], diastolic dysfunc-
tion [15-17], left ventricle ejection fraction [15-17],
peripheral neuropathy [18,19], cardiorespiratory reflexes
[20], gastroparesy [21], as well as stabilization of the dia-
betic retinopathy [22,23].
Transplant vs Dialysis for type 2 Diabetic Patients
Regarding patients with chronic kidney failure that are
under renal replacement therapy, data collected from the
USRDS (United States Renal Data System) from 1988
through 1996 indicated a 23% decrease in the mortality
rates of the patients awaiting a deceased donor kidney
transplant, which was also associated with a 30% decrease
in the mortality rates of the patients submitted to kidney
transplant [24]. Nowadays, one-thrid of the kidney trans-
plant patients in the United States of America and also in
Brazil has diabetes before the transplant. Despite the
transplant benefit, the probability of a cardiovascular
event after the transplant is higher in diabetic patients in
comparison to the general population [24].
In the United States of America, the kidney transplants in
type 2 diabetic patients are usually performed with
deceased donors, while only 20% are performed with liv-
ing donors [25]. It is also a reality in Brazil, inasmuch as
the diabetic patients show lower probability of having liv-
ing donors in the family, once there is a genetic predispo-
sition for diabetes. According to Wolfe at al, the mortality
after the kidney transplant, regardless of the age range
(2074 years old), is lower in comparison to the dialysis
therapy [26]. Dialysis is a well-known risk factor for mor-
tality because it contributes to the increased prevalence of
cardiovascular events.
After the kidney transplant, the type 2 diabetic patients
have 8 to 19 additional years in their life expectancy [26].
In addition, in American and non-American centers, there
is a growing trend towards transplants in the elderly
patients. The survival rates for either the patient or the kid-
ney graft are directly correlated to the recipient's age and
to the time of diabetes history, resulting in a reduction of
4 to 7% of the kidney graft survival rates (2002 United
States Organ Procurement and Transplantation Network
and the Scientific Registryof Transplant Recipients  OPTN/
SRTR Annual Report). As opposed to these data, other
authors demonstrated that in the type 2 diabetic patients,
the 1-year, 3-year and 5-year kidney graft survival rates
were similar to the non-diabetic patients (82.7% vs
87.6%; 70.9% vs 79%; 63% vs 72.5%, respectively) [27].
However, a bias of this study is that there were signifi-
cantly more living donors in the group of the diabetic
patients in comparison to the non-diabetics (33.5% vs
17.2%, respectively). In other study conducted with type
2 diabetic and non-diabetic patients, the patient survival
rates regarding kidney grafts from deceased donors were
68% vs 80% and from living donors were 81% vs 90%,
which suggests that the great differential seems to be the
recipients' age, which has affected both the diabetic and
the non-diabetic patients' survival rates [25]. Boucek et al
also reported that the patient survival rates in 1-year and
5-year for type 2 diabetic patients were compatible to 85%
and 69% respectively, and for the non-diabetic patients
the rates were 84% and 74%, respectively, being the differ-
ence not statiscally significant. In addition, the 1-year and
5-year kidney graft survival rates censored for death were
comparable between diabetics and non-diabetics (84% vs
82% and 77% vs 77%, repsctively) [28].
Post-Transplant Clinical Evolution
The causes of kidney graft loss after the first year of trans-
plant include chronic graft injury in 50% of the cases
(3040% chronic allograft dysfunction and 1020% recur-
rence of primary disease), and the other 50% represent the
death with a functioning kidney graft [29]. The physiopa-
thology of chronic kidney allograft dysfunction includes
mechanisms that involve either the alloantigens or the
non-alloantigenens factors, such as donors' demographic
data and events associated with the recipient, such as
infection, hypertension, obesity, diabetes itself, dyslipi-
demia, nephrotoxicity due to calcineurin inhibitors and
acute rejection episodes [29].
The main cause of mortality after the kidney transplant is
cardiovascular diseases (37%), followed by the cerebrov-
ascular diseases (7%), infections (20%), neoplasias
(13%) and other causes (23%). The yearly cardiovascular
mortality rate after the kidney transplant is 0.54% and for
patients undergoing dialytic treatment it is over 9%,
which is much higher in comparison to the general popu-
lation (0.28%).Page 3 of 7
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patients are associated with insulin resistance, higher val-
ues of triglycerides and lower values of HDL-cholesterol,
abnormalities in coagulation and fibrinolysis and
endothelial dysfunction, so that the time of type 2 diabe-
tes history has direct correlation to the mortality [30]. In
this way, for each increment of 1% glycated hemoglobin
in patients with 45 to 79 years old in a 6-year follow-up,
there is an increase of 26% in cardiovascular events, either
in men or in women [31]. As a matter of fact, even micro-
vascular complications occurrence increase with the wors-
ening of the glycated hemoglobin values [31].
More recent data demonstrated that the 5-year patient sur-
vival rate for type 2 diabetic patients was lower than the
non-diabetics' (70 vs 93%) [32]. When both groups were
compared, it was shown that type 2 diabetic patients were
older at the time of receiving the transplant, had higher
body mass index (BMI), higher prevalence of pretrans-
plant cardiovascular disease (48% vs 16%), and higher
incidence of posttransplant cardiovascular events (37% vs
9%). In addition, the main cause of death after the trans-
plant in type 2 diabetic patients included cardiovascular
disease (61% vs 26% for non-diabetics) [32]. Another
interesting aspect was the observation that infection was
the second cause of death after the transplant, and the dia-
betic patients also presented higher risk of mortality from
infection causes in comparison to the non-diabetics [32].
Thus, in the non-diabetics, the 5-year patient survival rates
after the transplant were mainly affected by the following
factors: recipients' age and dialysis background vs preemp-
tive transplant (transplant performed without previous
dialysis therapy), while in the diabetic patients, the back-
ground of dialysis and cardiovascular disease have also
influenced the patients' survival rates after the transplant
[32].
Additionally, the incidence of cardiovascular events after
the transplant in non-diabetic patients had a correlation
to the traditional factors, while for the diabetic patients
these cardiovascular events were associated with the pres-
ence of cardiovascular disease background [32].
For type 1 diabetic patients, it was demonstrated that 2-
year patient survival rate after kidney transplant in com-
parison to the dialysis therapy was not different, though
after the kidney transplant the lipid profile has improved
(lower triglycerides and cholesterol values), but the aver-
age carotid intima-media thickness was not different, as
opposed to the stabilization of the diabetic retinopathy in
over 90% of the cases [33]. These findings point out to the
benefits of the pancreas transplant for the type 1 diabetic
patients. Moreover, the simultaneous preemptive pancreas-
kidney transplant is associated with the longer survival
rates, either for the patient or for the kidney graft [34].
In the longer follow-up, 5-year patient and kidney graft
survival rates in type 1 diabetic patients that were submit-
ted to SPKT and in the non-diabetics submitted to kidney
transplant were 96% and 90%, and 85% and 75%, respec-
tively [35]. Such differences may be explained by the fact
that the the pancreas-kidney donors were younger and the
kidney cold ischemia time was shorter [35]. In Brazil, the
law determines that the pancreas-kidney donor is sup-
posed to be less than 45 years old and without a positive
family history of diabetes in the first degree relatives. In
addition, the pancreas is not allocated by the HLA com-
patibility, which contributes to the lower cold ischemia
times and consequently to lower rates of delayed graft
function. In our center, the mean cold ischemia times for
the kidney and the pancreas grafts are around 14 hours
[11]. On the other hand, for the isolated kidney trans-
plant, the cold ischemia time is approximately 24 hours,
inasmuch as the kidney allocation is determined by the
HLA compatibility.
After the SPKT, type 1 diabetic patients present a reduction
in the left ventricular mass in the first year of the trans-
plant, the glycated hemoglobin values also improve, as
well as the BMI, the triglycerides values and either the
systolic or the diastolic blood pressure control in compar-
ison to the patients submitted to the isolated kidney trans-
plant [13-17,36].
In addition, after 10 years the type 1 diabetic patients sub-
mitted to the SPKT in comparison to the isolated kidney
transplant present lower prevalence of vascular diseases,
including acute myocardial infarction, cerebrovascular
events and peripheral arterial disease associated with
amputation [37]. The 10-year survival of those patients
was statiscally superior to the patients that only had an
isolated kidney transplant (83% vs 70%) [37], probably
due to the lower progression of atherosclerosis [14]. These
findings were also reinforced by the reduction of the
carotid intima-media thickness after the SPKT, even
though it does not become normal [13]. Regarding the
peripheral vascular disease after the SPKT and isolated
kidney transplant, an aggravation occurs in both groups,
which is initially higher in the patients who have per-
formed SPKT [38], probably due to the hyperinsulinemia,
which may accelerate the atherosclerosis. It is also
reported that amputation rates after the SPKT in type 1
diabetic patients are reported as 8.8 to 9.5% [39,40]. In
type 2 diabetic patients under dialysis therapy, the yearly
amputation rate is 6.1% and increases to 11.3% when the
vascular disease is present on the occasion of kidney trans-
plant [41]. So, in patients with pretransplant amputation,
the risk of another amputation increases after the trans-
plant.
Regarding autonomic neuropathy, after the SPKT, there is
an improvement that starts after two years, which may jus-Page 4 of 7
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the SPKT patients in comparison to the isolated kidney
transplant patients, i.e., 80% vs 20%, respectively [42].
However, more severe cases of autonomic neuropathy do
not seem to present benefits from the transplant in rela-
tion to the patient survival [42].
Another discussed topic is if there is a room for glucose
improvement after pancreas transplant in type 2 diabetic
patients. In one study, the 5-year and 10-year survival
rates for type 2 diabetic patients who were submitted to
the SPKT were not different in comparison to the type 1
diabetic patients that were also submitted to the SPKT
[43]. Yet, the number of patients evaluated was small and
the definition criterion of the type 1 or 2 diabetes was
based on C-peptide values lower or higher than 0.8 ng/
mL, respectively, which is not sufficient to differentiate
the diabetes types.
Another study has recently shown that 17% of the type 1
diabetic patients had hyperglycemia after the pancreas
transplant, which has also occurred in 45% of the type 2
diabetic patients [44]. The risk factors for hyperglycemia
after the pancreas transplant were associated with the type
of transplant (SPKT vs PAKT and pancreas transplant
alone), with type 2 diabetes vs type 1 diabetes history,
with the pretansplant insulin dose and BMI, and with the
acute rejection episodes occurrence [44]. By analyzing the
BMI through the insulin dose prior to the transplant, it
was observed that the BMI greater than 28 kg/m2 and daily
insulin dose greater than 70 U, regardless of the diabetes
type (1 or 2), were the ones that had hyperglycemia in 80
to 90% of the times [44]. Thus, the indication for the pan-
creas transplant in those patients should be very cautious.
The conclusion is that the type 1 diabetic patients that pre-
sented lower BMI and lower insulin dose in the pretrans-
plant period were the ones that developed hyperglycemia
less frequently, i.e., approximately in 11% [44].
After the transplant, the approach to the diabetic patients
must be aggressive in relation to the systemic blood pres-
sure control, weight control through diet and exercise, dis-
continuing smoking, proteinuria control, dyslipidemia
control and hyperglycemia treatment, so that all the goals
established prior to the transplant should be pursued in
the posttransplant period [45]. Optimizing the conserva-
tive treatment measures and the approach with specific
medications, such as Losartan, are associated with the
decrease in the TGF-β expression in the kidney, which is a
fibrosis marker, and with the reduction of proteinuria and
consequently with the progression of chronic kidney allo-
graft dysfunction [46]. Furthermore, the weight loss and
the regular physical activity are associated with the
improvement in the insulin sensitivity.
Glitazones are also associated with the reduction of insu-
lin resistance and with the preservation of the beta cells
mass. Besides, they have impact on the reduction of the
cardiovascular risks and death rates of the patients with
chronic kidney failure [47], further reducing the proteinu-
ria and the systemic blood pressure. However, the post-
transplant use of glitazones still requires more studies,
especially in patients who are under corticosteroids treat-
ment because the risk fracture due to osteoporosis may be
elevated with these drugs.
Conclusion
Type 1 and 2 diabetic patients show higher survival rates
after transplant in comparison to the dialysis therapy,
although the prevalence of cardiovascular events and
infectious complications remain higher posttransplant
than in the general population.
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